https://pharminent.com/astrazeneca-says-drug-pricing-is-evolving-in-response-to-trumps-most-favored-nation-policy/ 2026-07-27T20:49:30Z Pharminent en AstraZeneca Says Drug Pricing Is 'Evolving' in Response to Trump's Most-Favored-Nation Policy 2026-07-27T20:41:01Z Blog https://pharminent.com/astrazenecas-ultomiris-misses-main-goal-in-transplant-tma-trial/ 2026-07-27T20:40:58Z Pharminent en AstraZeneca's Ultomiris Misses Main Goal in Transplant-TMA Trial 2026-07-27T20:40:58Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-27-2026/ 2026-07-27T20:26:33Z Pharminent en Rare Disease & Gene Therapy Digest • July 27, 2026 2026-07-27T20:26:31Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-july-25-2026/ 2026-07-27T19:22:19Z Pharminent en Week in Review • INTELLIGENCE BRIEF • July 25, 2026 2026-07-27T19:22:17Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-27-2026/ 2026-07-27T16:10:08Z Pharminent en Strategic News Watch • July 27, 2026 2026-07-27T16:10:07Z Blog https://pharminent.com/argenx-deepens-immuno-expertise-with-2-2b-forte-biosciences-buy/ 2026-07-27T20:31:13Z Pharminent en Argenx deepens immuno expertise with $2.2B Forte Biosciences buy 2026-07-27T12:23:54Z Blog https://pharminent.com/outlook-finally-claims-fda-approval-for-amd-drug/ 2026-07-27T16:06:25Z Pharminent en Outlook finally claims FDA approval for AMD drug 2026-07-27T11:26:18Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-24-2026/ 2026-07-25T18:52:07Z Pharminent en Oncology Intelligence Digest • July 24, 2026 2026-07-25T18:52:06Z Blog